Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
3,393people with obesity, in this paper
The trial randomly assignedassigned by chance
IDegLira
insulin degludec
Lowered long-term blood sugar−0.79
Lowered body weight−1.62
Lowered fasting blood sugar−0.45
randomisedthe abstract, start to end
… in significant reductions in HbA1c (MD -0.79%, 95%CI: -1.03% to -0.54%), body weight (MD -1.62 kg, 95% CI: -2.13 kg to -1.11 kg), fasting plasma glucose (MD -0.45 mmol/L, 95% CI: -0.77 mmol/L to -0.14 mmol/L), self-measured plasma glucose (MD -1.00 mmol/L, 95% CI: -1.42 mmol/L to -0.59 mmol/L), and systolic blood pressure (MD -2.23 mmHg, 95% CI: -3.63 mmHg to …
← favours treatmentfavours comparator →
could be chanceHbA1cIDegLira vs insulin degludec
−0.79−1.03 to −0.54
Body weightIDegLira vs insulin degludec
−1.62−2.13 to −1.11
Fasting plasma glucoseIDegLira vs insulin degludec
−0.45−0.77 to −0.14
Self-measured plasma glucoseIDegLira vs insulin degludec
−1.00−1.42 to −0.59
Systolic blood pressureIDegLira vs insulin degludec
−2.23−3.63 to −0.82
InsulinGlycemic controlBody weight & compositionBlood pressure
1 / 4